IMMURON LTD-SPON ADR (IMRN) Fundamental Analysis & Valuation
NASDAQ:IMRN • US45254U1016
Current stock price
0.793 USD
-0.01 (-0.88%)
At close:
0.793 USD
0 (0%)
After Hours:
This IMRN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. IMRN Profitability Analysis
1.1 Basic Checks
- IMRN had negative earnings in the past year.
- IMRN had a negative operating cash flow in the past year.
- In the past 5 years IMRN always reported negative net income.
- IMRN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -30.69%, IMRN is in the better half of the industry, outperforming 64.60% of the companies in the same industry.
- Looking at the Return On Equity, with a value of -35.53%, IMRN is in the better half of the industry, outperforming 70.99% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.69% | ||
| ROE | -35.53% | ||
| ROIC | N/A |
ROA(3y)-37.77%
ROA(5y)-31.16%
ROE(3y)-46.18%
ROE(5y)-36.64%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- IMRN has a Gross Margin of 63.69%. This is in the better half of the industry: IMRN outperforms 77.95% of its industry peers.
- IMRN's Gross Margin has declined in the last couple of years.
- IMRN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.69% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.49%
GM growth 5Y-2.08%
2. IMRN Health Analysis
2.1 Basic Checks
- IMRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, IMRN has more shares outstanding
- The number of shares outstanding for IMRN has been increased compared to 5 years ago.
- There is no outstanding debt for IMRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- IMRN has an Altman-Z score of -4.50. This is a bad value and indicates that IMRN is not financially healthy and even has some risk of bankruptcy.
- IMRN has a worse Altman-Z score (-4.50) than 61.70% of its industry peers.
- IMRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.5 |
ROIC/WACCN/A
WACC9.65%
2.3 Liquidity
- IMRN has a Current Ratio of 8.04. This indicates that IMRN is financially healthy and has no problem in meeting its short term obligations.
- With a decent Current ratio value of 8.04, IMRN is doing good in the industry, outperforming 71.37% of the companies in the same industry.
- A Quick Ratio of 6.83 indicates that IMRN has no problem at all paying its short term obligations.
- With a decent Quick ratio value of 6.83, IMRN is doing good in the industry, outperforming 65.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.04 | ||
| Quick Ratio | 6.83 |
3. IMRN Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 41.93% over the past year.
- IMRN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.30%.
- Measured over the past years, IMRN shows a very strong growth in Revenue. The Revenue has been growing by 23.67% on average per year.
EPS 1Y (TTM)41.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.78%
Revenue 1Y (TTM)14.3%
Revenue growth 3Y111.96%
Revenue growth 5Y23.67%
Sales Q2Q%4.76%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. IMRN Valuation Analysis
4.1 Price/Earnings Ratio
- IMRN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. IMRN Dividend Analysis
5.1 Amount
- No dividends for IMRN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
IMRN Fundamentals: All Metrics, Ratios and Statistics
0.793
-0.01 (-0.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26 2026-02-26
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner Change0%
Ins Owners7.03%
Ins Owner ChangeN/A
Market Cap6.41M
Revenue(TTM)7.48M
Net Income(TTM)-4.65M
Analysts0
Price TargetN/A
Short Float %0.42%
Short Ratio1.2
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.22 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.7 | ||
| P/tB | 0.7 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.45
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS0.65
BVpS1.14
TBVpS1.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.69% | ||
| ROE | -35.53% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.69% | ||
| FCFM | N/A |
ROA(3y)-37.77%
ROA(5y)-31.16%
ROE(3y)-46.18%
ROE(5y)-36.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.49%
GM growth 5Y-2.08%
F-Score3
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.04 | ||
| Quick Ratio | 6.83 | ||
| Altman-Z | -4.5 |
F-Score3
WACC9.65%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)0.14%
Cap/Sales(5y)1.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.78%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)14.3%
Revenue growth 3Y111.96%
Revenue growth 5Y23.67%
Sales Q2Q%4.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-30.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-30.21%
OCF growth 3YN/A
OCF growth 5YN/A
IMMURON LTD-SPON ADR / IMRN Fundamental Analysis FAQ
What is the fundamental rating for IMRN stock?
ChartMill assigns a fundamental rating of 3 / 10 to IMRN.
What is the valuation status for IMRN stock?
ChartMill assigns a valuation rating of 0 / 10 to IMMURON LTD-SPON ADR (IMRN). This can be considered as Overvalued.
What is the profitability of IMRN stock?
IMMURON LTD-SPON ADR (IMRN) has a profitability rating of 2 / 10.